Handa Pharmaceuticals, Inc. (TPEX:6620)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
79.60
+0.90 (1.14%)
Mar 3, 2026, 1:30 PM CST
-11.85%
Market Cap 12.38B
Revenue (ttm) 1.62B
Net Income (ttm) 683.16M
Shares Out 157.33M
EPS (ttm) 4.53
PE Ratio 17.36
Forward PE n/a
Dividend 1.51 (1.89%)
Ex-Dividend Date n/a
Volume 335,370
Average Volume 412,238
Open 79.20
Previous Close 78.70
Day's Range 78.30 - 80.30
52-Week Range 55.00 - 154.00
Beta 0.84
RSI 42.00
Earnings Date Apr 24, 2026

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis a... [Read more]

Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6620
Full Company Profile

Financial Performance

In 2024, Handa Pharmaceuticals's revenue was 830.67 million, a decrease of -24.92% compared to the previous year's 1.11 billion. Earnings were 472.74 million, a decrease of -34.96%.

Financial Statements

News

There is no news available yet.